ストックスクリーナーアプリを入手
48.19
2.38%
1.12
アフターアワーズ：
48.33
0.14
+0.29%
前日終値:
$47.07
開ける：
$48.27
24時間の取引高:
34.69M
Relative Volume:
2.73
時価総額：
$163.37B
収益：
$43.59B
当期純損益:
$15.04B
株価収益率:
14.27
EPS:
3.3766
ネットキャッシュフロー:
$10.74B
1週間 パフォーマンス:
-32.79%
1か月 パフォーマンス:
-30.98%
6か月 パフォーマンス:
-42.94%
1年 パフォーマンス:
-63.62%
1日の値動き範囲:
$47.55
$49.03
1週間の範囲:
$46.90
$71.28
52週間の値動き範囲:
$46.90
$139.74
Novo Nordisk Adr Stock (NVO) Company Profile
NVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
48.19 | 209.15B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
LLY
Lilly Eli Co
|
762.33 | 664.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
167.33 | 396.75B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
195.22 | 333.89B | 58.33B | 3.76B | 15.39B | 2.10 |
|
NVS
Novartis Ag Adr
|
115.30 | 220.18B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
79.29 | 196.16B | 63.62B | 16.41B | 17.04B | 6.49 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-04-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | アップグレード | Kepler | Hold → Buy |
| 2025-03-03 | ダウングレード | Stifel | Buy → Hold |
| 2025-02-12 | 開始されました | Morgan Stanley | Equal-Weight |
| 2025-01-06 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-12 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Neutral |
| 2023-12-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 開始されました | Argus | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2022-07-15 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | ダウングレード | UBS | Neutral → Sell |
| 2022-06-27 | アップグレード | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-05-31 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-04-25 | アップグレード | Cowen | Market Perform → Outperform |
| 2022-04-12 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-01-25 | ダウングレード | Liberum | Hold → Sell |
| 2021-12-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-12-17 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-01-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-07-06 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-05-11 | ダウングレード | UBS | Buy → Neutral |
| 2020-05-04 | 開始されました | Cowen | Market Perform |
| 2020-03-16 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-11-18 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-09-17 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-30 | ダウングレード | Jefferies | Hold → Underperform |
| 2019-06-20 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2019-06-11 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-04-29 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 開始されました | Exane BNP Paribas | Outperform |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2017-12-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2017-12-06 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
すべてを表示
Novo Nordisk Adr (NVO) 最新ニュース
HIMS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Kessler Topaz Meltzer & Check, LLP - GlobeNewswire Inc.
How to monitor Novo Nordisk A s (b Shares) Adrhedged with trend dashboardsFree Portfolio Diversification Stock Ideas - Newser
Is Novo Nordisk A s (b Shares) Adrhedged Stock a Smart Buy in 2025 Investment Analysis InsideIntraday Strategy with Real Time Monitoring - Newser
When is Novo Nordisk A s (b Shares) Adrhedged stock expected to show significant growthExpert Picks Review With Low Risk - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/SNVO - FinancialContent
Real time scanner hits for Novo Nordisk A s (b Shares) Adrhedged explainedFree Access to Real-Time Trade Insights - Newser
Is Novo Nordisk A s (b Shares) Adrhedged trending in predictive chart modelsFree Breakout Confirmation With Entry Tracker - Newser
Novo Nordisk A s (b Shares) Adrhedged’s volatility index tracking explainedSmart Chart Forecasting with AI Algorithms - Newser
Is Novo Nordisk A s (b Shares) Adrhedged a growth stock or a value stockBreakout Stocks Tracker For Consistent Profits - jammulinksnews.com
Is Novo Nordisk A s (b Shares) Adrhedged stock overvalued or undervaluedExpert Picks Outlook To Watch Now - jammulinksnews.com
Earnings visualization tools for Novo Nordisk A s (b Shares) AdrhedgedSwing Trade Watchlist with Entry Zones - Newser
Why Novo Nordisk A s (b Shares) Adrhedged stock attracts strong analyst attentionIntraday Price Action Forecast Planner - Newser
Will Novo Nordisk A s (b Shares) Adrhedged benefit from macro trendsFree Oversold Recovery Opportunity Stocks - Newser
The stock price plunged more than 20% when Novo Nordisk, the developer of the famous obesity drug We.. - 매일경제
Will earnings trigger a reversal in Novo Nordisk A s (b Shares) AdrhedgedFree News Based Entry Opportunity Alerts - Newser
The stock price plunged more than 20% as Novo Nordisk, the developer of the famous obesity drug WeGo.. - 매일경제
Using AI based signals to follow Novo Nordisk A s (b Shares) AdrhedgedTrading Volume Spike and Reversal Analysis - Newser
Will Novo Nordisk A s (b Shares) Adrhedged Benefit From Broader Market BounceTriple Return Setup With Risk Control Explained - metal.it
HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
Novo Nordisk Falls On Lowered Guidance. Pharma Giant Names New CEO. - Investor's Business Daily
Novo Nordisk ADR: Navigating Market Fluctuations with a 181.64B Market Cap - investchronicle.com
Bollinger Bands Show Potential Breakout in Novo Nordisk A s (b Shares) AdrhedgedProfit Target Stock Opportunity Monitor Activated - metal.it
Wall Street Today: Nasdaq, S&P hit record high; Sofi, Novo Nordisk, UnitedHealth shares in focus after Q2 results - MSN
Novo Nordisk Slumps While Philips Shines In European ADRs - Finimize
Novo Nordisk: Lower 2025 Guidance Reflects Persistent Competition From Compounded Semaglutide - Morningstar
Novo Nordisk: Lower 2025 Guidance Reflects Persistent Competition from Compounded Semaglutide - Morningstar
Novo Nordisk's Cardiometabolic Portfolio, Led by Semaglutide, Looks Underappreciated - Morningstar
Here’s What Happened The Last Time Novo Nordisk Stock Was This Oversold - Barchart.com
Published on: 2025-07-29 13:38:20 - metal.it
What institutional investors are buying Novo Nordisk A s (b Shares) Adrhedged stockLow Risk Forecasts For Smart Trading - jammulinksnews.com
How many analysts rate Novo Nordisk A s (b Shares) Adrhedged as a “Buy”Value Investing Entry Points With Proven Results - jammulinksnews.com
Novo Nordisk Adr (NVO) 財務データ
収益
当期純利益
現金流量
EPS
0.60%
大文字化:
|
ボリューム (24 時間):